<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fidaxomicin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fidaxomicin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fidaxomicin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16497" href="/d/html/16497.html" rel="external">see "Fidaxomicin: Drug information"</a> and <a class="drug drug_patient" data-topicid="16783" href="/d/html/16783.html" rel="external">see "Fidaxomicin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13120424"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dificid</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871347"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dificid</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13270093"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Macrolide</span></li></ul></div>
<div class="block dop drugH1Div" id="F54018702"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c05ef37d-c875-44c5-bf42-41a4ee5c44d5">
<i>Clostridioides difficile</i> infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides </i>
<i>difficile </i>infection (CDI), treatment: Note:</b> Fidaxomicin is only recommended in the setting of multiple recurrences in pediatric patients, as data and experience are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>). In patients ≥18 years, fidaxomicin is recommended as a first-line treatment option for an initial episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing:</i> Limited data available: Infants ≥6 months and Children: Oral: 16 mg/kg/dose twice daily for 10 days; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28575523','lexi-content-ref-31773143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28575523','lexi-content-ref-31773143'])">Ref</a></span>). Dosing based on a multi-center, randomized, phase 3 trial comparing fidaxomicin to vancomycin in the treatment of CDI (n=142 [98 received fidaxomicin]; median age: 60 months [interquartile range: 24 to 132 months]); in the trial, patients ≥6 years received a fixed dose of 200 mg twice daily. Most efficacy endpoints, including clinical cure, were statistically similar between treatment groups, with a higher end of study cure rate seen in the fidaxomicin group; adverse events were similar between groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31773143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31773143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing:</i> Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">4 to &lt;7 kg: Oral: Oral suspension: 80 mg twice daily for 10 days.</p>
<p style="text-indent:-2em;margin-left:6em;">7 to &lt;9 kg: Oral: Oral suspension: 120 mg twice daily for 10 days.</p>
<p style="text-indent:-2em;margin-left:6em;">9 to &lt;12.5 kg: Oral: Oral suspension: 160 mg twice daily for 10 days.</p>
<p style="text-indent:-2em;margin-left:6em;">≥12.5 kg: Oral: Oral suspension, tablets: 200 mg twice daily for 10 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54018706"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary (minimal systemic absorption).</p></div>
<div class="block dohp drugH1Div" id="F54018707"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment is likely unnecessary due to low systemic absorption and lack of hepatic metabolism or elimination of parent compound and metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28575523','lexi-content-ref-31773143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28575523','lexi-content-ref-31773143'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F12923821"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16497" href="/d/html/16497.html" rel="external">see "Fidaxomicin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c05ef37d-c875-44c5-bf42-41a4ee5c44d5">
<i>Clostridioides difficile</i> infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For initial and recurrent nonfulminant infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>). If antibiotic(s) for a primary infection are essential, some experts extend <i>C. difficile</i> infection treatment one week beyond other antibiotic(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial infection:</i>
<b>Oral:</b> 200 mg twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>). If delayed response to treatment, a longer duration (eg, up to 14 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent infection:</i>
<b> Oral:</b> 200 mg twice daily for 10 days or 200 mg twice daily for 5 days, followed by 200 mg once every other day for 20 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164674'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992046"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (systemic absorption limited; minimal excretion by the kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (systemic absorption limited; minimal excretion by the kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (systemic absorption limited; minimal excretion by the kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (systemic absorption limited; minimal excretion by the kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989331"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's label (has not been studied); However, due to minimal systemic absorption no dosage adjustment predicted.</p></div>
<div class="block adr drugH1Div" id="F12923672"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (adults 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants, children, and adolescents: 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;5%), skin rash (adults: &lt;2%), urticaria (infants, children, and adolescents: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate (adults: &lt;2%), hyperglycemia (adults: &lt;2%), metabolic acidosis (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (adults: &lt;2%), abdominal pain (6% to 8%), abdominal tenderness (adults: &lt;2%), constipation (infants, children, and adolescents: 5%), diarrhea (infants, children, and adolescents: 7%), dyspepsia (adults: &lt;2%), dysphagia (adults: &lt;2%), flatulence (adults: &lt;2%), gastrointestinal hemorrhage (adults: 4%), intestinal obstruction (adults: &lt;2%), non-Hirschsprung megacolon (adults: &lt;2%), vomiting (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (adults: 2%), decreased platelet count (adults: &lt;2%), neutropenia (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (adults: ≤5%), increased serum alkaline phosphatase (adults: &lt;2%), increased serum transaminases (infants, children, and adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Fixed drug eruption (adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F12923669"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to fidaxomicin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F12923670"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (angioedema [mouth, face, throat], dyspnea, pruritus, and rash) to fidaxomicin have been reported. If a severe reaction occurs, discontinue drug and institute supportive care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macrolide allergy: Use with caution in patients with a history of macrolide allergy; may be at increased risk for hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not use for systemic infections; fidaxomicin systemic absorption is negligible. Use only in patients with proven or strongly suspected <i>C. difficile </i>infections.</p></div>
<div class="block foc drugH1Div" id="F13120425"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dificid: 40 mg/mL (136 mL) [contains sodium benzoate; mixed berry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dificid: 200 mg [contains soybean lecithin]</p></div>
<div class="block geq drugH1Div" id="F12923550"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322903"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Dificid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $43.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Dificid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $298.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871348"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dificid: 200 mg [contains soybean lecithin]</p></div>
<div class="block adip drugH1Div" id="F53570362"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Fidaxomicin is bactericidal against gram-positive anaerobes (including <i>C. difficile</i> NAP1/B1/027 strain) and gram-positive aerobes. Fidaxomicin spectrum does <b>not</b> include gram-negative aerobes or gram-negative anaerobes (eg, <i>Bacteroides spp</i>). At the approved doses, concentrations in feces substantially exceed the 90% minimum inhibitory concentration of <i>C. difficile</i>. Postantibiotic effects against <i>C. difficile</i> in clinical studies range from 6 to 10 hours. Clinical studies excluded patients with a history of &gt;1 recurrent <i>C. difficile</i>-associated diarrhea (CDAD) episode within 3 months.</p></div>
<div class="block admp drugH1Div" id="F54018708"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Remove bottle from refrigerator 15 minutes prior to each dose. Shake vigorously prior to measuring dose and check for even consistency. Measure and administer using an oral dosing syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Tablets may be crushed and mixed with 40 mL of water or applesauce, or 60 mL of Ensure for immediate administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25424419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25424419'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">G-tube/NG: Very limited experience reported; minimal product loss was observed after a single tablet was crushed, mixed into 40 mL of water, and passed through an NG tube followed by a water flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25424419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25424419'])">Ref</a></span>). In 1 case report, fidaxomicin tablets were crushed, mixed with water, and administered via G-tube to a 10 year old; clinical improvement was observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463209'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F12923824"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Remove from refrigerator 15 minutes prior to each administration. Shake vigorously before use; use oral dosing syringe for administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Tablet may be crushed and mixed with 40 mL of water or applesauce, or 60 mL of Ensure; administer as soon as possible after preparation (room temperature stability: 2 hours [water]; 24 hours [applesauce, Ensure]). Additionally, minimal product loss was observed after a tablet was crushed, mixed into 40 mL of distilled water, passed through an NG tube, and flushed with two 15 mL portions of water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25424419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25424419'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F12923774"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store reconstituted oral suspension at 2°C to 8°C (36°F to 46°F) for ≤12 days; discard after 12 days. Do not open pouch until time of use; store in original bottle.</p></div>
<div class="block usep drugH1Div" id="F53570935"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (FDA approved in ages ≥6 months and adults).</p></div>
<div class="block mst drugH1Div" id="F56685044"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fidaxomicin may be confused with rifAXIMin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299334"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F12931805"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F12923667"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The limited systemic absorption of fidaxomicin may limit potential fetal exposure.</p></div>
<div class="block mopp drugH1Div" id="F54018709"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of hypersensitivity reaction; liver function tests (if clinically indicated).</p></div>
<div class="block pha drugH1Div" id="F12923775"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits RNA polymerase sigma subunit resulting in inhibition of protein synthesis and cell death in susceptible organisms including <i>C. difficile</i>; bactericidal</p></div>
<div class="block phk drugH1Div" id="F12923777"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The pharmacokinetics of fidaxomicin in pediatric patients 6 months to &lt;18 years of age are similar to those in adult patients (O'Gorman 2018; Wolf 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Minimal systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Largely confined to the gastrointestinal tract; in single- and multiple-dose studies, fecal concentrations of fidaxomicin and its active metabolite (OP-1118) are very high while serum concentrations are minimally detectable to undetectable.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Intestinal hydrolysis to less active metabolite (OP-1118).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (&gt;92% as unchanged drug and metabolites); urine (&lt;1% as metabolite).</p></div>
<div class="block phksp drugH1Div" id="F51192565"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma concentrations were approximately 2- to 4-fold higher in elderly patients versus nonelderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059491"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dificid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dificid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dafclir</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dificid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dificid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dificlir</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dificid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fidicid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dificid.1">
<a name="Dificid.1"></a>Dificid (fidaxomicin) [prescribing information] Rahway, NJ: Merck Sharp &amp; Dohme LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164674">
<a name="34164674"></a>Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. <i>Clin Infect Dis</i>. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/34164674/pubmed" id="34164674" target="_blank">34164674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kelly.1">
<a name="Kelly.1"></a>Kelly CP, Lamont JT, Bakken JS. Clostridioides difficile infection in adults: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34003176">
<a name="34003176"></a>Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. <i>Am J Gastroenterol</i>. 2021b;116(6):1124-1147. doi:10.14309/ajg.0000000000001278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/34003176/pubmed" id="34003176" target="_blank">34003176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18955523">
<a name="18955523"></a>Louie TJ, Emery J, Krulicki W, et al. OPT-80 Eliminates <i>Clostridium difficile</i> and Is Sparing of Bacteroides Species During Treatment of <i>C. difficile</i> Infection. <i>Antimicrob Agents Chemother</i>. 2009;53(1):261-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/18955523/pubmed" id="18955523" target="_blank">18955523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23379974">
<a name="23379974"></a>Louie TJ, Miller MA, Crook DW, et al. Effect of Age on Treatment Outcomes in <i>Clostridium difficile</i> Infection. <i>J Am Geriatr Soc</i>. 2013;61(2):222-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/23379974/pubmed" id="23379974" target="_blank">23379974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288078">
<a name="21288078"></a>Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin Versus Vancomycin for <i>Clostridium difficile</i> Infection. <i>N Engl J Med</i>. 2011;364(5):422-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/21288078/pubmed" id="21288078" target="_blank">21288078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18955525">
<a name="18955525"></a>Louie T, Miller M, Donskey C, et al. Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial With Patients With <i>Clostridium difficile</i> Infection. <i>Antimicrob Agents Chemother</i>. 2009;53(1):223-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/18955525/pubmed" id="18955525" target="_blank">18955525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28575523">
<a name="28575523"></a>O'Gorman MA, Michaels MG, Kaplan SL, et al. Safety and pharmacokinetic study of fidaxomicin in children with Clostridium difficile-associated diarrhea: a phase 2a multicenter clinical trial. <i>J Pediatric Infect Dis Soc</i>. 2018;7(3):210-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/28575523/pubmed" id="28575523" target="_blank">28575523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18268081">
<a name="18268081"></a>Shue YK, Sears PS, Shangle S, et al. Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers Following Single and Multiple Oral Doses. <i>Antimicrob Agents Chemother</i>. 2008;52(4):1391-1395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/18268081/pubmed" id="18268081" target="_blank">18268081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463209">
<a name="23463209"></a>Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. <i>J Antimicrob Chemother</i>. 2013;68(7):1688-1689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/23463209/pubmed" id="23463209" target="_blank">23463209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20071495">
<a name="20071495"></a>Sullivan KM, Spooner LM. Fidaxomicin: A Macrocyclic Antibiotic for the Management of <i>Clostridium difficile</i> Infection. <i>Ann Pharmacother</i>. 2010;44(2):352-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/20071495/pubmed" id="20071495" target="_blank">20071495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439232">
<a name="23439232"></a>Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of <i>Clostridium difficile</i> Infections. <i>Am J Gastroenterol</i>. 2013;108(4):478-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/23439232/pubmed" id="23439232" target="_blank">23439232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20724385">
<a name="20724385"></a>Tannock GW, Munro K, Taylor C, et al. A New Macrocyclic Antibiotic, Fidaxomicin (OPT-80), Causes Less Alteration to the Bowel Microbiota of <i>Clostridium difficile</i>-Infected Patients Than Does Vancomycin. <i>Microbiology.</i> 2010;156(pt 11):3354-3359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/20724385/pubmed" id="20724385" target="_blank">20724385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25424419">
<a name="25424419"></a>Tousseeva A, Jackson JD, Redell M, et al. Stability and recovery of DIFICID(®) (fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. <i>Drugs R D</i>. 2014;14(4):309-314. doi:10.1007/s40268-014-0067-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/25424419/pubmed" id="25424419" target="_blank">25424419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31773143">
<a name="31773143"></a>Wolf J, Kalocsai K, Fortuny C, et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). <i>Clin Infect Dis</i>. Published online November 27, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fidaxomicin-pediatric-drug-information/abstract-text/31773143/pubmed" id="31773143" target="_blank">31773143</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126625 Version 55.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
